Artemisinic acid

CAS# 80286-58-4

Artemisinic acid

Catalog No. BCN4336----Order now to get a substantial discount!

Product Name & Size Price Stock
Artemisinic acid: 5mg $81 In Stock
Artemisinic acid: 10mg Please Inquire In Stock
Artemisinic acid: 20mg Please Inquire Please Inquire
Artemisinic acid: 50mg Please Inquire Please Inquire
Artemisinic acid: 100mg Please Inquire Please Inquire
Artemisinic acid: 200mg Please Inquire Please Inquire
Artemisinic acid: 500mg Please Inquire Please Inquire
Artemisinic acid: 1000mg Please Inquire Please Inquire

Quality Control of Artemisinic acid

Number of papers citing our products

Chemical structure

Artemisinic acid

3D structure

Chemical Properties of Artemisinic acid

Cas No. 80286-58-4 SDF Download SDF
PubChem ID 124033 Appearance Powder
Formula C15H22O2 M.Wt 234.3
Type of Compound Sesquiterpenoids Storage Desiccate at -20°C
Solubility DMSO : 100 mg/mL (426.75 mM; Need ultrasonic)
Chemical Name 2-[(4R)-4,7-dimethyl-1,2,3,4,4a,5,6,8a-octahydronaphthalen-1-yl]prop-2-enoic acid
SMILES CC1CCC(C2C1CCC(=C2)C)C(=C)C(=O)O
Standard InChIKey PLQMEXSCSAIXGB-GOHLOCJQSA-N
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Source of Artemisinic acid

The herb of Artemisia annua L.

Biological Activity of Artemisinic acid

DescriptionArtemisinic acid, is the immediate precursor of the semi-synthesis artemisinin, could be a cost-effective, environmentally friendly, high-quality and reliable source of artemisinin. Artemisinic acid has a variety of pharmacological activity, such as antimalarial, anti-tumor, antipyretic, antibacterial, allelopathy and anti-adipogenesis effects. Artemisinic acid is a regulator of adipocyte differentiation and C/EBP δ expression, it inhibits adipogenic differentiation of hAMSCs through reduced expression of C/EBP δ; it inhibits melanogenesis through downregulation of C/EBP α-dependent expression of HMG-CoA reductase gene.
TargetsTyrosinase | cAMP | PKA | HMG-CoA Reductase | PPAR | JNK | VEGFR | P450 (e.g. CYP17) | Antifection | C/EBP δ
In vitro

Artemisinic acid is a regulator of adipocyte differentiation and C/EBP δ expression.[Pubmed: 22396222]

J Cell Biochem. 2012 Jul;113(7):2488-99.

Adipocyte dysfunction is associated with the development of obesity. In this study, Artemisinic acid, which was isolated from Artemisia annua L., inhibited adipogenic differentiation of human adipose tissue-derived mesenchymal stem cells (hAMSCs) and its mechanism of action was determined.
METHODS AND RESULTS:
The mRNA levels of peroxidase proliferation-activated receptor (PPAR) γ and CCAAT/enhancer binding protein (C/EBP) α, late adipogenic factors, were reduced by Artemisinic acid. Moreover, the mRNA levels of the PPAR γ target genes lipoprotein lipase, CD36, adipocyte protein, and liver X receptor were down-regulated by Artemisinic acid. Artemisinic acid reduced expression of the C/EBP δ gene without impacting C/EBP β. In addition, attempts to elucidate a possible mechanism underlying the Artemisinic acid-mediated effects revealed that reduced expression of the C/EBP δ gene was mediated by inhibiting Jun N-terminal kinase (JNK). Additionally, Artemisinic acid also reduced the expression of the adipogenesis-associated genes glucose transporter-4 and vascular endothelial growth factor. In addition to the interference of Artemisinic acid with adipogenesis, Artemisinic acid significantly attenuated tumor necrosis factor-α-induced secretion of interleukin-6 by undifferentiated hAMSCs, thus influencing insulin resistance and the inflammatory state characterizing obesity.
CONCLUSIONS:
Taken together, these findings indicate that inhibiting adipogenic differentiation of hAMSCs by Artemisinic acid occurs primarily through reduced expression of C/EBP δ, which is mediated by the inhibition of JNK and suggest that aremisinic acid may be used as a complementary treatment option for obesity associated with metabolic syndrome.

Antimicrobial activity of artemisinin and its precursors.[Reference: WebLink]

Current Science, 2000 , 78 (6) :709-713.

Artemisinic acid and Arteannuin B are biogenetic precursors of Artemisinin, an important antimalarial produced by the herb Artemisia annua. These compounds have been screened for antimicrobial activity against a range of organisms.
CONCLUSIONS:
All the three compounds are active against different bacteria and certain fungal species

Protocol of Artemisinic acid

Kinase Assay

Artemisinic acid inhibits melanogenesis through downregulation of C/EBP α-dependent expression of HMG-CoA reductase gene.[Pubmed: 23063590]

Food Chem Toxicol. 2013 Jan;51:225-30.

Cholesterol is associated with the regulation of melanogenesis which is the major physiological defense against solar irradiation. The present study was designed to determine the effects of Artemisinic acid on melanogenesis and its mechanisms of action in human epidermal melanocytes.
METHODS AND RESULTS:
In this study, we found that Artemisinic acid inhibited melanin content. The mRNA levels of microphthalmia-associated transcription factor (MITF) and its downstream genes tyrosinase, tyrosinase-related protein (TRP)-1, and TRP-2 were reduced by Artemisinic acid treatment. Additionally, the mRNA levels of melanogenesis-related genes (c-KIT, stem cell factor (SCF), and macrophage migration inhibitory factor (MIF)) were down-regulated by Artemisinic acid. Furthermore, cAMP production and protein kinase A (PKA) activity were suppressed by Artemisinic acid. Moreover, attempts to elucidate a possible mechanism underlying the Artemisinic acid-mediated effects revealed that Artemisinic acid regulated melanogenesis by inhibiting cholesterol synthesis through downregulation of the hydroxymethylglutaryl CoA (HMG CoA) reductase gene, which was mediated through reduced expression of the CCAAT/enhancer-binding protein (C/EBP) α gene.
CONCLUSIONS:
Taken together, these findings indicate that the inhibition of melanogenesis by Artemisinic acid occurs through reduced expression of the HMG CoA reductase gene, which is mediated by C/EBP α inhibition and suggest that Artemisinic acid may be useful as a hyperpigmentation inhibitor.

Structure Identification
Nature. 2006 Apr 13;440(7086):940-3.

Production of the antimalarial drug precursor artemisinic acid in engineered yeast.[Pubmed: 16612385 ]

Malaria is a global health problem that threatens 300-500 million people and kills more than one million people annually. Disease control is hampered by the occurrence of multi-drug-resistant strains of the malaria parasite Plasmodium falciparum. Synthetic antimalarial drugs and malarial vaccines are currently being developed, but their efficacy against malaria awaits rigorous clinical testing. Artemisinin, a sesquiterpene lactone endoperoxide extracted from Artemisia annua L (family Asteraceae; commonly known as sweet wormwood), is highly effective against multi-drug-resistant Plasmodium spp., but is in short supply and unaffordable to most malaria sufferers. Although total synthesis of artemisinin is difficult and costly, the semi-synthesis of artemisinin or any derivative from microbially sourced Artemisinic acid, its immediate precursor, could be a cost-effective, environmentally friendly, high-quality and reliable source of artemisinin.
METHODS AND RESULTS:
Here we report the engineering of Saccharomyces cerevisiae to produce high titres (up to 100 mg l(-1)) of Artemisinic acid using an engineered mevalonate pathway, amorphadiene synthase, and a novel cytochrome P450 monooxygenase (CYP71AV1) from A. annua that performs a three-step oxidation of amorpha-4,11-diene to Artemisinic acid. The synthesized Artemisinic acid is transported out and retained on the outside of the engineered yeast, meaning that a simple and inexpensive purification process can be used to obtain the desired product.
CONCLUSIONS:
Although the engineered yeast is already capable of producing Artemisinic acid at a significantly higher specific productivity than A. annua, yield optimization and industrial scale-up will be required to raise Artemisinic acid production to a level high enough to reduce artemisinin combination therapies to significantly below their current prices.

Artemisinic acid Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

Artemisinic acid Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of Artemisinic acid

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 4.268 mL 21.3402 mL 42.6803 mL 85.3606 mL 106.7008 mL
5 mM 0.8536 mL 4.268 mL 8.5361 mL 17.0721 mL 21.3402 mL
10 mM 0.4268 mL 2.134 mL 4.268 mL 8.5361 mL 10.6701 mL
50 mM 0.0854 mL 0.4268 mL 0.8536 mL 1.7072 mL 2.134 mL
100 mM 0.0427 mL 0.2134 mL 0.4268 mL 0.8536 mL 1.067 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University
Featured Products
New Products
 

References on Artemisinic acid

Production of the antimalarial drug precursor artemisinic acid in engineered yeast.[Pubmed:16612385]

Nature. 2006 Apr 13;440(7086):940-3.

Malaria is a global health problem that threatens 300-500 million people and kills more than one million people annually. Disease control is hampered by the occurrence of multi-drug-resistant strains of the malaria parasite Plasmodium falciparum. Synthetic antimalarial drugs and malarial vaccines are currently being developed, but their efficacy against malaria awaits rigorous clinical testing. Artemisinin, a sesquiterpene lactone endoperoxide extracted from Artemisia annua L (family Asteraceae; commonly known as sweet wormwood), is highly effective against multi-drug-resistant Plasmodium spp., but is in short supply and unaffordable to most malaria sufferers. Although total synthesis of artemisinin is difficult and costly, the semi-synthesis of artemisinin or any derivative from microbially sourced Artemisinic acid, its immediate precursor, could be a cost-effective, environmentally friendly, high-quality and reliable source of artemisinin. Here we report the engineering of Saccharomyces cerevisiae to produce high titres (up to 100 mg l(-1)) of Artemisinic acid using an engineered mevalonate pathway, amorphadiene synthase, and a novel cytochrome P450 monooxygenase (CYP71AV1) from A. annua that performs a three-step oxidation of amorpha-4,11-diene to Artemisinic acid. The synthesized Artemisinic acid is transported out and retained on the outside of the engineered yeast, meaning that a simple and inexpensive purification process can be used to obtain the desired product. Although the engineered yeast is already capable of producing Artemisinic acid at a significantly higher specific productivity than A. annua, yield optimization and industrial scale-up will be required to raise Artemisinic acid production to a level high enough to reduce artemisinin combination therapies to significantly below their current prices.

Artemisinic acid inhibits melanogenesis through downregulation of C/EBP alpha-dependent expression of HMG-CoA reductase gene.[Pubmed:23063590]

Food Chem Toxicol. 2013 Jan;51:225-30.

Cholesterol is associated with the regulation of melanogenesis which is the major physiological defense against solar irradiation. The present study was designed to determine the effects of Artemisinic acid on melanogenesis and its mechanisms of action in human epidermal melanocytes. In this study, we found that Artemisinic acid inhibited melanin content. The mRNA levels of microphthalmia-associated transcription factor (MITF) and its downstream genes tyrosinase, tyrosinase-related protein (TRP)-1, and TRP-2 were reduced by Artemisinic acid treatment. Additionally, the mRNA levels of melanogenesis-related genes (c-KIT, stem cell factor (SCF), and macrophage migration inhibitory factor (MIF)) were down-regulated by Artemisinic acid. Furthermore, cAMP production and protein kinase A (PKA) activity were suppressed by Artemisinic acid. Moreover, attempts to elucidate a possible mechanism underlying the Artemisinic acid-mediated effects revealed that Artemisinic acid regulated melanogenesis by inhibiting cholesterol synthesis through downregulation of the hydroxymethylglutaryl CoA (HMG CoA) reductase gene, which was mediated through reduced expression of the CCAAT/enhancer-binding protein (C/EBP) alpha gene. Taken together, these findings indicate that the inhibition of melanogenesis by Artemisinic acid occurs through reduced expression of the HMG CoA reductase gene, which is mediated by C/EBP alpha inhibition and suggest that Artemisinic acid may be useful as a hyperpigmentation inhibitor.

Artemisinic acid is a regulator of adipocyte differentiation and C/EBP delta expression.[Pubmed:22396222]

J Cell Biochem. 2012 Jul;113(7):2488-99.

Adipocyte dysfunction is associated with the development of obesity. In this study, Artemisinic acid, which was isolated from Artemisia annua L., inhibited adipogenic differentiation of human adipose tissue-derived mesenchymal stem cells (hAMSCs) and its mechanism of action was determined. The mRNA levels of peroxidase proliferation-activated receptor (PPAR) gamma and CCAAT/enhancer binding protein (C/EBP) alpha, late adipogenic factors, were reduced by Artemisinic acid. Moreover, the mRNA levels of the PPAR gamma target genes lipoprotein lipase, CD36, adipocyte protein, and liver X receptor were down-regulated by Artemisinic acid. Artemisinic acid reduced expression of the C/EBP delta gene without impacting C/EBP beta. In addition, attempts to elucidate a possible mechanism underlying the Artemisinic acid-mediated effects revealed that reduced expression of the C/EBP delta gene was mediated by inhibiting Jun N-terminal kinase (JNK). Additionally, Artemisinic acid also reduced the expression of the adipogenesis-associated genes glucose transporter-4 and vascular endothelial growth factor. In addition to the interference of Artemisinic acid with adipogenesis, Artemisinic acid significantly attenuated tumor necrosis factor-alpha-induced secretion of interleukin-6 by undifferentiated hAMSCs, thus influencing insulin resistance and the inflammatory state characterizing obesity. Taken together, these findings indicate that inhibiting adipogenic differentiation of hAMSCs by Artemisinic acid occurs primarily through reduced expression of C/EBP delta, which is mediated by the inhibition of JNK and suggest that aremisinic acid may be used as a complementary treatment option for obesity associated with metabolic syndrome.

Description

Artemisinic acid (Qing Hao acid), an amorphane sesquiterpene isolated from Artemisia annua L., possesses a variety of pharmacological activity, such as antimalarial activity, anti-tumor activity, antipyretic effect, antibacterial activity, allelopathy effect and anti-adipogenesis effect.

Keywords:

Artemisinic acid,80286-58-4,Natural Products, buy Artemisinic acid , Artemisinic acid supplier , purchase Artemisinic acid , Artemisinic acid cost , Artemisinic acid manufacturer , order Artemisinic acid , high purity Artemisinic acid

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: